A nanoparticle does double duty, imaging and treating atherosclerosis

The researchers present their work today at the 251st National Meeting & Exposition of the American Chemical Society (ACS).

"Other researchers have shown that if you isolate HDL components from donated blood, reconstitute them and inject them into animals, there seems to be a therapeutic effect," says Shanta Dhar, Ph.D. "However, with donors' blood, there is the chance of immunological rejection. This technology also suffers scale-up challenges. Our motivation was to avoid immunogenic factors by making a synthetic nanoparticle which can functionally mimic HDL. At the same time, we wanted a way to locate the synthetic particles."

Current detection strategies often fail to identify dangerous plaques, which can clog arteries over time or break off from arterial walls and block blood flow, causing a heart attack or stroke. Magnetic resonance imaging (MRI) offers a potential approach for plaque visualization, but requires the use of a contrast agent to show the atherosclerotic plaques clearly. But the potential for harmful immune reactions still exists with the use of donor-derived HDL.

Beyond imaging, there is a therapeutic aspect of using HDL. HDL is widely known as "good" cholesterol because of its ability to pull low-density lipoprotein, or "bad" cholesterol, out of plaques. This process shrinks the plaques, making them less likely to clog arteries or break apart.

To simultaneously identify and treat atherosclerosis without triggering an immune response, Dhar and Bhabatosh Banik, Ph.D., a postdoctoral fellow in her lab, created an MRI-active HDL mimic. The researchers, who are at the University of Georgia, Athens, had previously built synthetic HDL particles lacking a contrast agent. These particles lowered levels of total cholesterol and triglycerides in mice.

"The key challenge, then, was designing the contrast agent," Banik says. "It took time to figure out the optimal lipophilicity and solubility." The contrast agent, iron oxide, needs to be encapsulated in the synthetic lipoparticle's hydrophobic core to provide the brightest possible signal. Eventually, the researchers hit on the right chemical combination -- iron oxide with a fatty surface coating -- for optimal particle encapsulation. They successfully visualized the contrast agent using MRI in cell studies.

The researchers are applying their synthetic nanoparticle to distinguish between unstable plaques and stationary ones. To do this, Dhar targeted the new MRI-active HDL mimics to macrophages, which are white blood cells that, along with lipids and cholesterol, make up atherosclerotic plaques.

The researchers targeted macrophages by decorating the nanoparticles' surfaces with a molecule that selectively binds to macrophages. The team observed that the nanoparticles were engulfed by these white blood cells. "Then, when the macrophages ruptured, which is a sign of an unstable plaque, the cells spit out the nanoparticles, causing the MRI signal to change in a detectable fashion," Banik says.

Dhar says her lab is now using MRI to study how well the particles light up and treat plaques in animals, and she hopes to begin clinical trials within two years.